Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa

Pittsburgh (USA) 3 October (PROTEXT/PRNewswire) - Mylan Inc. (NYSE: MYL)yesterday announced the appointment of Didier Barret to the position ofPresident, EMEA (Europe, Middle East and Africa) following the completionof Mylan's acquisition of Merck's Generics Group today.

At Merck Generics, M. Barret most recently served as Region Director, EMEA,reporting to the CEO. He was promoted to that position in 2004 followinghis role as Area Director for Southern Europe, where he was responsible forFrance, Belgium, Italy, Spain and Portugal. He established Merck Generics'first operations in France in 1995, growing the business to exceed euro 341million in sales by 2006. Prior to this, M. Barret held several positionswithin Merck's branded division, including sales and marketing in the UKand France.

Mylan Vice Chairman and CEO, Robert J. Coury, commented: "We are verypleased to welcome Didier to the senior leadership team at Mylan. He is aphenomenal operator and leader, having created Merck Generic's business inFrance literally from nothing to becoming the strong and growing businessit is today. Under his leadership of the EMEA region since 2004, growthfrom operations in these territories has been extremely impressive, ataround 12% annual compound growth. As we take our place as a global leaderin the generics and specialty pharmaceutical industry, Didier will play akey role in ensuring that we maximize our many opportunities for growth andsuccess moving forward in the EMEA region."

M. Barret said: "I am very excited to be part of the new Mylan. There is areal cultural fit between our organizations and the new management teamunder Robert is very much operating with a unified vision. Together, ourcombined company is truly a world leader in our industry, with the depthand scale in terms of product portfolio and pipeline, as well asmanufacturing and R&D, to provide our customers, and ultimately patients,with the best quality products and service available. I look forward tobeing a part of Mylan's future success. I also want to take the opportunityto thank my teams in EMEA for their hard work and the contributions eachhas made to the success of our business to date and for their commitment tomaking the new Mylan even more successful in the future."

Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and aglobal commercial footprint through operations in more than 90 countries.

Through its controlling interest in Matrix Laboratories Limited, Mylan hasdirect access to one of the largest active pharmaceutical ingredient (API)manufacturers in the world. Dey L.P., Mylan's fully integrated specialtybusiness, provides the Company with innovative and Diversifiedopportunities in the respiratory and allergy therapeutic areas.

With manufacturing, packaging, distribution and marketing capabilities,Mylan EMEA holds leading positions in several fast-growing marketsthroughout Europe including France, Germany, United Kingdom, Italy, Spain,Austria, Greece, Ireland, Belgium, Netherlands, Portugal, Scandinavia, aswell as South Africa and Morocco.

For more information about Mylan, please visit http://www.mylan.com.

Web site: http://www.mylan.com

Source: Mylan Inc.

Contact: Kris King, Mylan Inc., tel.: +1-724-514-1800

Subscribers please note that material bearing the label "PROTEXT" is notpart of CTK's news service and is not to be published under the "CTK"label. Protext is a commercial service providing distribution of pressreleases from clients, who are identified in the text of Protext reportsand who bear full responsibility for their contents.

PROTEXT